Shanghai Obio Technology (Group) Corp., Ltd. (SHA:688238)
China
· Delayed Price · Currency is CNY 6.83
+0.12 (1.79%)
At close: Apr 29, 2026
SHA:688238 Revenue
In the year 2025, Shanghai Obio Technology (Group) Corp. had annual revenue of 267.70M CNY with 7.88% growth. Shanghai Obio Technology (Group) Corp. had revenue of 87.34M in the quarter ending December 31, 2025, with 35.88% growth.
Revenue
267.70M
Revenue Growth
+7.88%
P/S Ratio
16.22
Revenue / Employee
383.51K
Employees
678
Market Cap
4.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 267.70M | 19.55M | 7.88% |
| Dec 31, 2024 | 248.15M | 43.34M | 21.16% |
| Dec 31, 2023 | 204.81M | -86.50M | -29.69% |
| Dec 31, 2022 | 291.30M | 36.36M | 14.26% |
| Dec 31, 2021 | 254.95M | 112.18M | 78.57% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pulike Biological Engineering | 1.10B |
| Hefei Lifeon Pharmaceutical | 1.47B |
| Beijing Bohui Innovation Biotechnology Group | 824.58M |
| Boji Medical Technology | 949.94M |
| Hinova Pharmaceuticals | 46.50M |
| Assure Tech (Hangzhou) | 453.58M |
| Baolingbao Biology | 2.81B |
| Guanhao Biotech | 387.75M |